Vertex Announces Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated +1.04%

Vertex Pharmaceuticals Incorporated




Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via